Correction to: Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study.

IF 11 1区医学 Q1 DERMATOLOGY British Journal of Dermatology Pub Date : 2024-11-18 DOI:10.1093/bjd/ljae366

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

更正：阿达木单抗、英夫利昔单抗、赛库单抗和乌司他单抗在化脓性扁桃体炎中的长期药物存活率：一项丹麦全国性队列研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

British Journal of Dermatology 医学-皮肤病学

CiteScore

16.30

自引率

3.90%

发文量

1062

审稿时长

2-4 weeks

期刊介绍： The British Journal of Dermatology (BJD) is committed to publishing the highest quality dermatological research. Through its publications, the journal seeks to advance the understanding, management, and treatment of skin diseases, ultimately aiming to improve patient outcomes.

期刊最新文献

Bright yellow dots in children. Guselkumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients: results of the phase 3, randomized, placebo-controlled PROTOSTAR study. Haematohidrosis. Optimal in vitro models as a basis for understanding and more effective treatment of infantile hemangiomas. Pilot study of topical ruxolitinib demonstrates efficacy and blunting of heterogeneous inflammatory processes in mild hidradenitis suppurativa.